Browsing by Autor "Huber Padilla-Zambrano"

Now showing 1 - 2 of 2

Biomarkers in acute brain trauma: A narrative review
(Medknow, 2019) Amit Agrawal; Gabriel Alexander Quiñones-Ossa; Huber Padilla-Zambrano; Ranabir Pal; Amrita Ghosh; Luis Rafael Moscote‐Salazar; VA Kiran Kumar
Biomarkers have been used to diagnose, prognose, evaluate, and identify the severity and outcomes in traumatic brain injury (TBI) patients. This study explored if it is possible to predict the outcome of TBI patients by estimating the biomarkers in cerebrospinal fluid and serum. We searched data bases and literature about biomarkers, and found forty epidemiologic studies from 92 potentially relevant articles. However, limited data are available about postanoxic encephalopathy. It showed that presently, neurofilament, S100B, glial fibrillary acidic protein, and ubiquitin carboxyl terminal hydrolase-L1 seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-Tau, neuron-specific enolase, S100B, glial fibrillary acidic protein, and spectrin breakdown products appear to be candidates for reflective biomarkers of TBI. Point-of-care biomarkers are needed in TBI which is one of the most important additional risk factors in road traffic injuries. In a holistic approach, more researches about biomarkers of TBI are required. These biomarkers are very useful for treatment of patients with TBI.
Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis
(Elsevier BV, 2025) Magdalena Ruiz; Mourice Morcos; Víctor Castillo; Ana Karen Treviño-Morales; Jessica Edith Acevedo-Rodriguez; María Susana Cerino-Peñaloza; Annaliz Flores-Saldivar; María Camila Vargas-Hernández; Huber Padilla-Zambrano; Rosario Salazar‐Riojas
Abstract Introduction Beta thalassemia is an inherited blood disorder caused by mutations in the genes encoding beta globin. In transfusion-dependent patients, transfusions can lead to iron overload, associated with organ damage and increased mortality. Luspatercept has emerged as a promising therapeutic agent to reduce the need for transfusions and to improve iron management in these patients. Objective Evaluate the efficacy of luspatercept versus placebo in reducing transfusion burden and liver iron concentration (LIC) in patients with transfusion-dependent beta-thalassemia. Methods A systematic search was performed in Pubmed, Embase and Cochrane for studies comparing luspatercept versus placebo in patients with transfusion-dependent beta-thalassemia. The main outcomes of interest were reduction of transfusion burden by ≥33% and ≥50% and LIC. Statistical analysis was performed using Review Manager. The I2 test was used to assess heterogeneity, and risk of bias was assessed using ROBINS-I. Results We included 368 patients from two clinical trials. The use of luspatercept was associated with a higher proportion of patients achieving both ≥33% (RR = 2.22; 95%CI 1.70-2.89; p = 0.00001) and ≥50% (RR= 6.22; 95%CI 3.28-11.80; p = 0.00001) reduction in transfusion burden compared to the placebo group. Regarding LIC, no statistically significant difference was observed when comparing both groups (mean difference: 1.33 mg/g; 95% CI -0.79 to 3.45; p = 0.22) Conclusion Luspatercept demonstrated significant efficacy in reducing transfusion requirement in patients with transfusion-dependent beta-thalassemia. Although no clear effect on LIC was demonstrated, the results support its use as a promising alternative. Nevertheless, these findings should be interpreted with caution, as one of the studies did not include a placebo group, which limits the robustness of the comparison. Further confirmation by additional randomized clinical trials is needed to validate these results and to determine in more detail their role in clinical practice.